Lead sponsor
MedImmune LLC
15 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
15
Trials led
0
Active
1,005
Total enrollment
57
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
7
Phase 1/2
1
Phase 2
7
Trials by status
Completed
15
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy VolunteersBMI 22-30Ph 1Completed362
A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus—Ph 1/2Completed113
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.BMI ≥30Ph 2Completed74
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.BMI 27-40Ph 2Completed65
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.BMI 27-40Ph 2Completed51
A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese ParticipantsBMI ≥35Ph 1Completed51
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 DiabetesBMI 25-40Ph 2Completed49
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well ToleratedBMI 25-45Ph 2Completed41
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment SubjectsBMI ≥17Ph 1Completed37
A Study Investigating the Pharmacokinetics of a Single Dose Administration of CotadutideBMI 19-30Ph 1Completed36
A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese DescentBMI 23-40Ph 1Completed32
A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes MellitusBMI 28-40Ph 2Completed28
A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382BMI 19-30Ph 1Completed24